Google AI

Weekend Times


The Times

PR Newswire

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC

  • Written by: PR Newswire Asia - The Times Au RSS
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC

DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.

The clinical study was conducted in Australia from 2016- 2017.  In the study, 25% of the patients had stable disease and 40% of the patients had relief from brain edema. The data from the study suggested the possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema.

In 2017, PharmAbcine received approval from the US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. Furthermore, Olinvacimab received Orphan Drug Designation (ODD) from both the US FDA and the Korean MFSD (Ministry of Food and Drug Safety) in 2018. Beginning in 2019, the Phase II clinical trial is currently on-going.

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor with a fast growth rate. Recurrent glioblastoma multiforme (rGBM) is a disease in which the GBM recur after surgery and drug/radiation therapy. It is known that rGBM has an average life expectancy of about 4 months and causes extensive brain edema.

About Society of Neuro-Oncology Annual Meeting

Society of Neuro-Oncology Annual Meeting is the world's largest neuro-oncology society held every year. This year marks 25th event with more than 2600 researchers and experts participating from more than 40 countries around the world. Through this event, many global pharmaceutical companies will present various cutting-edge technologies and advance their academic and research efforts in the field of neuro-oncology. SNO 2020 will be held virtually from November 19 to 21.

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services.

For additional information about PharmAbcine, visit http://www.pharmabcine.com[1].

View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmabcine-to-present-the-final-data-of-phase-iia-rgbm-trial-at-sno-2020-301172595.html[2]

Read more https://www.prnasia.com/story/archive/3190840_CN90840_0

The Weekend Times Magazine

Laser Skin Clinic Kew: Advanced Treatments for Radiant, Healthy Skin

With advancements in modern cosmetic treatments, people no longer need to rely solely on skincare products to achieve visible results. Professional clinics offering laser technology have become trusted destinations for...

Buying Your First Pontoon Boat? Here's What to Look For!

If you're a water lover and eager to cruise peaceful inland waterways more often, a pontoon boat is a great way to do it. Plus, it's largely considered the easiest...

The Aussie Man Launches Debut Range of Men’s Grooming Products

Brand new Australian made men’s skincare company The Aussie Man has today announced the launch of their new range of organic skincare.  The Aussie Man uses hero natural ingredients such as...

Top Applications of Sandstone Crazy Pavers

Crazy paving may not seem like an expensive flooring option, but it is well worth your attention and thought. It refers to the ‘crazed’ appearance of a completed area and...

Niacinamide: Skincare’s Ultimate Multitasker

One ingredient, multiple uses: why niacinamide is this year’s most relevant skincare ingredient Niacinamide—also known as vitamin B3—is celebrated as skincare’s brilliant all-rounder. A relative newcomer in commercial cosmetic formulations, this...

How Legal Representation Helps Solve Family Disputes

Family disputes can be some of the most challenging legal matters individuals face. Issues involving separation, parenting arrangements, property division, and family responsibilities often involve both legal complexities and emotional...

The Best Camera Smartphones for 2021

Everyone is a photographer these days, and it is no surprise, given that the top camera phones on the market are capable of fighting head-on with luxury compact cameras and...

Ensuring a consistent Australian foreign policy - Scott Morrison

The Morrison Government will introduce new legislation to ensure the arrangements states, territories, councils and universities have with foreign governments are consistent with Australian foreign policy.   The Commonwealth Government has exclusive...

The official ANZ launch of EPOS

Sydney - Following a panel discussion with Australian businessman Mark Bouris and panellists Alyce Tran, Scott Bidmead and Jahan Sheikh from Microsoft EPOS was launched. Attendees experienced...

hacklink esim new zealandBetimgrandpashabet girişzlibraryz libraryjojobetcialis 20 mg fiyat